Among these, alpha-1 antitrypsin (AAT) deficiency remains the most established endotype biomarker and treatable trait in COPD, with serum AAT levels serving to identify patients eligible for augmentation therapy [28]. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.